Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism

Transplantation

Volumn 68, Issue 4, 1999, Pages 480-484

  Spitzer, Thomas R ^a   Delmonico, Francis ^a   Tolkoff Rubin, Nina ^a   McAfee, Steven ^a   Sackstein, Robert ^a   Saidman, Susan ^a   Colby, Christine ^a   Sykes, Megan ^a   Sachs, David H ^a   Cosimi, A Benedict ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CASE REPORT; CHIMERA; FEMALE; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MULTIPLE MYELOMA; PRIORITY JOURNAL;

BONE MARROW TRANSPLANTATION; CHIMERA; FEMALE; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032852141     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199908270-00006     Document Type: Article

References (40)

1. Dunn J, Golden D, Van Buren CT, et al. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990; 49: 349.
2. Basadonna GP, Matas JA, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1994; 99: 109.
4. Bock HA, Gallati H, Zurcher RM, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation 1995; 59: 830.
5. Tilney NL. Thoughts on the immunobiology of chronic allograft rejection. Transplant Proc 1995; 27: 2123.
6. Colson YL, Wren SM, Schuchert MJ, et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol 1995; 155: 4179.
7. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989; 169: 493.
8. de Vries-van der Zwan A, Besseling AC, de Waal LP, Boog CJ. Specific tolerance induction and transplantation: a single-day protocol. Blood 1997; 89: 2596.
9. Gammie JS, Li S, Zeevi A, et al. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts. Circulation 1998; 98: II163-8; discussion II168-9.
10. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256.
11. Kimikawa M, Sachs DH, Colvin RB, et al. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709.
12. Khan A, Tomita Y, Sykes M. Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance. Transplantation 1996; 62: 380.
13. Sayegh MH, Fine NA, Smith JL, et al. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114: 954.
14. Brennan DC, Mohanakumar T, Flye MW. Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: a review of efficacy and mechanisms. Am J Kidney Dis 1995; 26: 701.
15. Powles RL, Morgenstern GR, Kay HE, et al. Mis matched family donor for bone marrow transplantation and acute leukemia. Lancet 1983; 1: 612.
16. Beatty PG, Clift FM, Mickelson BB, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765.
17. Pelot MR, Pearson DA, Swenson K, et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease. Biol Blood Marrow Transplant 1999; 5: 133.
18. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988; 168: 2391.
19. Sykes M, Preffer F, Saidman SL, et al. Mixed Lymphohematopoietic chimerism is achievable following non-myeloablative therapy and HLA-mismatched donor marrow transplantation. Lancet 1999; 353: 1755.
20. Schwartz DWM, Glock B, Jungl EM, Mayr WR. Strategy to detect chimerism in allogeneic bone marrow transplant recipients by PCR amplification fragment length polymorphism analysis of microsatellite polymorphisms. Vox Sang 1995; 68: 139.
21. Jarman AP, Nicholls RD, Weatherall DJ, et al. Molecular characterization of a hypervariable region downstreat of the human alpha-globulin gene cluster. EMBO J 1986; 5: 1857.
22. Guzzetta PC, Sundt TM, Suzuki T, et al. Induction of kidney transplantation tolerance across major histocompatibility complex barriers by bone marrow transplantation in miniature swine. Transplantation 1991; 51: 862.
23. Smith CV, Nakajima K, Mixon A, et al. Successful induction of long-term specific tolerance to fully allogeneic renal allografts in miniature swine. Transplantation 1992; 53: 438.
24. Helf C, Chapuis B, Bolle J, et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic BMT. Transplantation 1994; 58: 1420.
25. Jacobsen N, Taaning E, Ladeforge J, Pedersen F. Tolerance to an HLA-B, DR dispartate kidney allograft after BMT from same donor. Lancet 1994; 1: 800.
26. Sorof J, Koerper M, DeSantes K, Cowan M. Renal Transplantation without chronic immunosuppression after T-cell depleted, H:A-mis-matched bone marrow transplantation. Transplantation 1995; 59: 1633.
27. Dey B, Sykes M, Spitzer TR. Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine (Balt). 1998; 77: 355.
28. Garcia-Morales R, Esquenazi K, Zucker Y, et al. An assessment of effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation 1996; 62: 1149.
29. Garcia-Morales R, Carreno M, Mathew JM, et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest 1997; 99: 1118.
30. Rugeles MT, Aitouche A, Zeevi A, et al. Evidence for the presence of multilineage chimerism and progenitors of donor dendritic cells in the peripheral blood of bone marrow-augmented organ transplant recipient. Transplantation 1997; 64: 735.
31. Garcia-Morales R, Carreno M, Mathew JM, et al. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation 1998; 65: 956.
32. Tura S, Cavo M, Rosti G, et al. Allogeneic bone marrow transplantation for multiple myeloma. Bone Marrow Transplant 1989; 4 (suppl 4): 106.
33. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991; 325: 1267.
34. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312.
35. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787.
36. Giralt SE, E., Albitar M, Van Besien K, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531.
37. Khouri IF, Keating M, Korbling M, et al. Transplant-Lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817.
38. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alterative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756.
39. Tomita Y, Khan A, Sykes M. Mechanism by which additional monoclonal antibody (mAB) injections overcome the requirement for thymic irradiation to achieve mixed chimerism in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. Transplantation 1996; 61: 477.
40. Manilay JO, Pearson DA, Sergio JJ, et al. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 1998; 66: 96.